Hualan Biological Engineering (002007) Q3 2026 earnings summary

Executive summary

• Q3 revenue fell 35.75% YoY to ¥1.016bn; attributable net profit declined 82.41% to ¥47.25m. YTD revenue was ¥2.582bn, down 23.58%, and attributable net profit was ¥430.60m, down 45.11%.

• YTD plasma collection volume increased 15% YoY, while higher VAT, weaker market demand and lower influenza-vaccine pricing pressured results.

Financial highlights

• Q3 attributable net profit excluding non-recurring items was ¥42.03m, down 83.74% YoY; YTD adjusted attributable net profit was ¥383.98m, down 48.28%.

• YTD operating profit was ¥549.73m versus ¥1.008bn a year earlier; consolidated net profit was ¥429.06m versus ¥827.70m.

• YTD operating cash flow was ¥372.65m, down 17.30% YoY.

Segment performance

• Plasma collection volume rose 15% YoY in 9M 2026, supporting future development capacity.

• Investee Hualan Ankang reported 9M revenue of ¥268.17m, up 35.76%; bevacizumab sales were ¥240.84m, up 81.86%, and net profit was ¥18.16m.

• Influenza-vaccine offerings shifted from quadrivalent to trivalent for the season, with corresponding terminal price adjustments and discounted supply for a rural free-vaccination program targeting older adults and children.